September 2012

Temozolomide for relapsed primary CNS lymphoma.

Asif Husain Osmani
Aga Khan University, asif.osmani@aku.edu

Nehal l Masood
Aga Khan University, nehal.masood@aku.edu

Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med

Part of the Hematology Commons, and the Oncology Commons

Recommended Citation
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_med_med/215
INTRODUCTION

Primary CNS lymphoma accounts for 3% of all primary brain tumours with median age of onset of about 62 years.1 The disease is more common in men (the male-to-female ratio is 2:1). The nature, intensity, and duration of immune suppression are factors in determining the risk of developing PCNSL. Patients with AIDS who have low CD4+ counts are at the greatest risk for PCNSL. It is an aggressive form of non-Hodgkin’s lymphoma that develops within brain, spinal cord, eye or leptomeninges without evidence of systemic involvement. In majority of the cases, it presents as unifocal and multifocal enhancing lesions on MRI, frequently adjacent to ventricles. Biopsy is the diagnostic procedure of choice revealing high-grade malignant non-Hodgkin’s B-cell lymphoma in more than 90% cases. Pathologically, it is an angiocentric neoplasm composed of a dense monoclonal proliferation of lymphocytes usually diffuse large B cells.2 Despite recent progress, results following the treatment for primary CNS lymphoma patients remain disappointing, typically producing a 5 years survival rate of 22-40%.3 Chemotherapy followed by radiotherapy is the cornerstone of first line treatment of primary CNS lymphoma.4,5 The principal agent in its management is high dose methotrexate (HD MTX) which yields 30-65% complete responses.6 As no other simple agent is prospectively proven active against primary CNS lymphoma, it is presently impossible to attribute a therapeutic benefit of any single agent apart from HD MTX. Temozolomide is an oral alkylating agent that spontaneously undergoes clinical conversion of the cytotoxic metabolite MTIC (5-[3-methyl-1-triazeno] imidazole-4-carboxamide) at physiological Ph, without metabolic conversion. Temozolomide depletes methyltransferase in various cell types. Temozolomide activity against primary CNS lymphoma has been (anecdotally) reported.7 We present a case of primary CNS lymphoma which progressed on various chemotherapy regimens but responded to a single agent temozolomide.

CASE REPORT

A 42 years old gentleman with no medical or family history presented to Emergency Room in 2007 with a single episode of generalized tonic clonic seizures followed by unconsciousness. After regaining consciousness there was no neurological deficit and no lymph nodes palpable on examination. From HD MTX. Temozolomide is an oral alkylating agent that spontaneously undergoes clinical conversion of the cytotoxic metabolite MTIC (5-[3-methyl-1-triazeno] imidazole-4-carboxamide) at physiological Ph, without metabolic conversion. Temozolomide depletes methyltransferase in various cell types. Temozolomide activity against primary CNS lymphoma has been (anecdotally) reported.7 We present a case of primary CNS lymphoma which progressed on various chemotherapy regimens but responded to a single agent temozolomide.
took the option of gamma knife stereotactic surgery, which lead to further deterioration of his symptoms. Subsequently he was treated with salvage high dose methotrexate. Patient improved clinically after two cycles and MRI also showed responsive disease. After completion of six cycles imaging showed slight progression of disease (Figure 1A). At this time he was switched to salvage temozolomide 150 mg/m² per orally daily for 5 days a month. After three cycles imaging showed complete resolution of disease, but patient was experiencing frequent episode of headaches, so the dose of temozolomide was decreased to 100 mg/m². On completion of his tenth cycle the brain imaging again showed resolution of disease (Figure 1B).

The patient remained in remission 3 years from his initial presentation and has a good quality of life. He has no neurological deficit, has normal mental functions and is not dependant for daily chores.

**DISCUSSION**

Primary CNS lymphoma has an aggressive course. The prognosis of patients with relapse or refractory CNSL is even poorer and with median survival of only 2 months. Methotrexate is the most effective agent against primary CNS lymphoma. It is used in combination with other drugs such as vincristine, procarbazine, cytarabine and rituximab. High dose MTX 3.5 gm/m² overcomes blood brain barrier. It is followed by consolidation radiation as initial treatment to maximize response and improve outcomes. Radiation results in tumour regression as well as partial repair and closure of blood brain barrier behind the tumour. HD-MTX in primary CNS lymphoma has substantially improved the survival of patients with the disease. Salvage therapy with HD-MTX appears to be effective for patients with CNS lymphoma who relapse after initial complete remission to MTX. In a study, overall response rate was 91% to first salvage HD-MTX and 100% to second salvage. Median survival was 61.9 months after first relapse and 91.9 months overall.

Temozolomide has also been effective as a single agent as salvage therapy in relapse primary CNS lymphoma. In a phase-2 trial assessing the activity of TMZ with recurrent primary CNS lymphoma, previously treated with HD-MTX containing chemotherapy and radiotherapy, 9 out of 36 patients had a complete response (25%; 95% CI 11-39%) and 2 had a partial response (6%; 95% CI 0-14%). The study was closed at this time as the target of 10 objective responses were achieved. Median progression-free survival was 2.8 months (interquartile range 1.8 months), median overall survival was 3.9 months (interquartile range 1.7-16 months) and 1-year overall survival was 31% (95% confidence interval 16-46%). In this study 28 patients (78%) had first recurrence and only 8 patients had multiple recurrent disease having failed to respond to other salvage treatment. Median number of cycles were 2 (range 1-12). Toxicities were mild; 2 patients had 1 episode of grade 4 neutropenia and 1 patient had grade 3 vomiting in a single cycle. None of the patients had headaches.

Single-agent temozolomide can be considered as salvage treatment for patients with primary CNS lymphoma. It is well tolerated in even patients with poor performance status. Its non-cumulative and modest toxicities makes it potentially useful agent for maintenance therapy.

**REFERENCES**